Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips

Iijima, Masumi; Kadoya, Hiroyasu; Hatahira, Satoko; Hiramatsu, Shingo; Jung, Giman; Martin, Aaron; Quinn, John; Jung, Joohee; Jeong, Seong‐Yun; Choi, Eun Kyung; Arakawa, Takeshi; Hinako, Fumiyo; Kusünoki, Masanobu; Yoshimoto, Nobuo; Niimi, Tomoaki; Tanizawa, Katsuyuki; Kuroda, Shinya

doi:10.1016/j.biomaterials.2010.10.057

Cited by 60 publications

(58 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…64 Cu-DOTA-trastuzumab injections passed quality control testing against the following specifications: radioactivity (.150 MBq), volume (3-4 mL), clarity (clear), color (none), pH (6)(7)(8), radiochemical purity (.95%), protein abundance (,100 mg), specific activity (.100 GBq/ mmol), sterility (Japanese Pharmacopoeia), and endotoxin (,0.25 EU/ mL). HER2 immunoreactivities (dissociation constants) of the final products were determined to be approximately 1 nM, as described previously (25), using a quartz-crystal microbalance (QCM, single Q0500; SCINICS) with analysis software (QCM1-2, version 1.22; SCINICS).…”

Section: Generalmentioning

confidence: 99%

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Tamura¹,

Kurihara

Yonemori³

et al. 2013

J Nucl Med

254

151

View full text Add to dashboard Cite

The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)-positive tumor images of 64 Cu-DOTA-trastuzumab in humans. Methods: PET was performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, and 48 h after injection of approximately 130 MBq of the probe 64 Cu-DOTA-trastuzumab. Radioactivity data were collected from the blood, urine, and normal-tissue samples of these 6 patients, and the multiorgan biodistribution and internal dosimetry of the probe were evaluated. Safety data were collected for all the patients after the administration of 64 Cu-DOTA-trastuzumab and during the 1-wk follow-up period. Results: According to our results, the best timing for the assessment of 64 Cu-DOTA-trastuzumab uptake by the tumor was 48 h after injection. Radiation exposure during 64 Cu-DOTA-trastuzumab PET was equivalent to that during conventional 18 F-FDG PET. The radioactivity in the blood was high, but uptake of 64 Cu-DOTA-trastuzumab in normal tissues was low. In 2 patients, 64 Cu-DOTA-trastuzumab PET showed brain metastases, indicative of blood-brain barrier disruptions. In 3 patients, 64 Cu-DOTA-trastuzumab PET imaging also revealed primary breast tumors at the lesion sites initially identified by CT. Conclusion: The findings of this study indicated that 64 Cu-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.

show abstract

Section: Generalmentioning

confidence: 99%

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Tamura¹,

Kurihara

Yonemori³

et al. 2013

J Nucl Med

254

151

View full text Add to dashboard Cite

show abstract

“…Preparation of α-DC-ZZ-BNCs 24 Armenian hamster IgGs were observed to be bound to ZZ-BNCs with high affinity (0.38 ± 0.07 mol per 1 mol ZZ-L protein), and rat IgG2a and IgG2b were weakly bound to ZZ-BNCs (0.02 ± 0.01 and 0.04 ± 0.02 mol per 1 mol ZZ-L protein, respectively). For the generation of stable α-DC-ZZ-BNC complexes, the chemical crosslinker BS 3 was added to the mixture of ZZ-BNCs and α-DC antibodies, as described previously.…”

Section: Resultsmentioning

confidence: 99%

“…24 Briefly, the sensor chip of the QCM consisted of a 9-mm-diameter disk made from an AT-cut 27-MHz quartz crystal with gold electrodes on both sides (diameter, 2.5 mm; area, 4.9 mm 2 ). A frequency change (∆F) of 1 Hz corresponded to a weight change of 0.6 ng/cm 2 .…”

Section: Quartz Crystal Microbalance (Qcm)mentioning

confidence: 99%

“…13 These results demonstrated that the α-CD11c-ZZ-BNC complexes could more promptly and efficiently accumulate in splenic DCs (in 62% of CD11c + splenocytes at 40 minutes after intravenous injection) than other DC-targeting nanocarriers. Because ZZBNCs could display antibodies in an oriented-immobilization manner and thereby significantly enhance the sensitivity, antigen-binding capacity, and affinity of the antibody itself, 24,26,27 complex formation by α-CD11c antibodies with ZZ-BNCs may improve the molecular recognition between CD11c molecules and DC-targeting nanocarriers.…”

Section: Next Cd11cmentioning

confidence: 99%

“…20,21 We have replaced the central part of the pre-S1 region (amino acid residues 51 to 159) of BNC with a tandem form of the IgG Fc-interacting region (Z domain) derived from Staphylococcus aureus protein A 22 to generate the ZZ-L protein 23 ( Figure 1A). The mutated BNC (ZZ-BNC) can tether IgG Fc regions and display IgG Fv regions outwardly for the effective binding of Ags in an oriented-immobilization manner ( Figure 1B), 24 while retaining membrane fusiogenic activity. ZZ-BNCs displaying α-epidermal growth factor receptor (EGFR) antibodies efficiently targeted EGFRoverexpressing glioblastoma in vivo following intracerebroventricular injection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Matsuo

Yoshimoto²,

Iijima³

et al. 2012

IJN

Self Cite

View full text Add to dashboard Cite

Dendritic cells (DCs) are key regulators of adaptive T-cell responses. By capturing exogenous antigens and presenting antigen-derived peptides via major histocompatibility complex molecules to naïve T cells, DCs induce antigen-specific immune responses in vivo. In order to induce effective host immune responses, active delivery of exogenous antigens to DCs is considered important for future vaccine development. We recently generated bionanocapsules (BNCs) consisting of hepatitis B virus surface antigens that mediate stringent in vivo cell targeting and efficient endosomal escape, and after the fusion with liposomes (LP) containing therapeutic materials, the BNC-LP complexes deliver them to human liver-derived tissues in vivo. BNCs were further modified to present the immunoglobulin G (IgG) Fc-interacting domain (Z domain) derived from Staphylococcus aureus protein A in tandem. When mixed with IgGs, modified BNCs (ZZ-BNCs) displayed the IgG Fv regions outwardly for efficient binding to antigens in an oriented-immobilization manner. Due to the affinity of the displayed IgGs, the IgG-ZZ-BNC complexes accumulated in specific cells and tissues in vitro and in vivo. After mixing ZZ-BNCs with antibodies against DCs, we used immunocytochemistry to examine which antibodies delivered ZZ-BNCs to mouse splenic DCs following intravenous injection of the ZZ-BNCs. ZZ-BNCs displaying anti-CD11c monoclonal antibodies (α-CD11c-ZZ-BNCs) were found to accumulate with approximately 62% of splenic DCs, and reside within some of them. After the fusion with liposomes containing antigens, the α-CD11c-ZZ-BNCs could elicit the respective antibodies more efficiently than other nontargeting control vaccines, suggesting that this DC-specific nanocarrier is promising for future vaccines.

show abstract

Bio‐nanocapsule‐based scaffold improves the sensitivity and ligand‐binding capacity of mammalian receptors on the sensor chip

Iijima

Yoshimoto

Niimi

et al. 2016

Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

Mammalian receptors are recognized as target molecules for drug discovery, and chemical libraries have been screened for both potential antagonists and agonists mainly by ligand-binding assays using immobilized receptors. A bio-nanocapsule (BNC) of approximately 30 nm that displays a tandem form of the protein A-derived immunoglobulin G (IgG) Fc-binding Z domains (denoted as ZZ-BNC) has been developed for both clustering and oriented immobilization of IgGs on the solid phase of immunosensors. In this study, human IgG1 Fc-fused vascular endothelial growth factor (VEGF) receptor was immobilized through ZZ-BNC on the sensor chip of quartz crystal microbalance (ZZ-BNC-coating). When compared with direct adsorption and protein A-coating, the sensor chip showed higher sensitivity (∽46- and ∽165-fold, respectively) and larger ligand-binding capacity (∽4- and ∽18-fold, respectively). Furthermore, the number of VEGF molecules bound to its receptor increased from 0.20 (direct adsorption) to 2.06 by ZZ-BNC-coating, strongly suggesting that ZZ-BNC reduced the steric hindrance near ligand recognition sites through oriented immobilization. Similarly, the sensitivity and ligand-binding capacity of leptin and prolactin receptors were both enhanced at a level comparable to that observed for the VEGF receptor. Thus, the combination of ZZ-BNC and Fc-fused receptors could significantly improve the function of ligand-binding assays.

show abstract

Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips

Cited by 60 publications

References 34 publications

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Bio‐nanocapsule‐based scaffold improves the sensitivity and ligand‐binding capacity of mammalian receptors on the sensor chip

Contact Info

Product

Resources

About

Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips

Cited by 60 publications

References 34 publications

64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells

Bio‐nanocapsule‐based scaffold improves the sensitivity and ligand‐binding capacity of mammalian receptors on the sensor chip

Contact Info

Product

Resources

About

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

⁶⁴Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer